Abstract
Targeted delivery of therapeutic and diagnostic agents to cancer sites has significant potential to improve the therapeutic outcome of treatment while minimizing severe side effects. It is widely accepted that decoration of the drug delivery systems with targeting ligands that bind specifically to the receptors on the cancer cells is a promising strategy that may substantially enhance accumulation of anticancer agents in the tumors. Due to the transformed cellular nature, cancer cells exhibit a variety of overexpressed cell surface receptors for peptides, hormones, and essential nutrients, providing a significant number of target candidates for selective drug delivery. Among others, luteinizing hormonereleasing hormone (LHRH) receptors are overexpressed in the majority of cancers, while their expression in healthy tissues, apart from pituitary cells, is limited. The recent studies indicate that LHRH peptides can be employed to efficiently guide anticancer and imaging agents directly to cancerous cells, thereby increasing the amount of these substances in tumor tissue and preventing normal cells from unnecessary exposure. This manuscript provides an overview of the targeted drug delivery platforms that take advantage of the LHRH receptors overexpression by cancer cells.
Keywords: Cancer, drug delivery systems, GnRH, LHRH, nanoparticles, targeted delivery.
Mini-Reviews in Medicinal Chemistry
Title:LHRH-Targeted Drug Delivery Systems for Cancer Therapy
Volume: 17 Issue: 3
Author(s): Xiaoning Li, Oleh Taratula, Olena Taratula, Canan Schumann and Tamara Minko
Affiliation:
Keywords: Cancer, drug delivery systems, GnRH, LHRH, nanoparticles, targeted delivery.
Abstract: Targeted delivery of therapeutic and diagnostic agents to cancer sites has significant potential to improve the therapeutic outcome of treatment while minimizing severe side effects. It is widely accepted that decoration of the drug delivery systems with targeting ligands that bind specifically to the receptors on the cancer cells is a promising strategy that may substantially enhance accumulation of anticancer agents in the tumors. Due to the transformed cellular nature, cancer cells exhibit a variety of overexpressed cell surface receptors for peptides, hormones, and essential nutrients, providing a significant number of target candidates for selective drug delivery. Among others, luteinizing hormonereleasing hormone (LHRH) receptors are overexpressed in the majority of cancers, while their expression in healthy tissues, apart from pituitary cells, is limited. The recent studies indicate that LHRH peptides can be employed to efficiently guide anticancer and imaging agents directly to cancerous cells, thereby increasing the amount of these substances in tumor tissue and preventing normal cells from unnecessary exposure. This manuscript provides an overview of the targeted drug delivery platforms that take advantage of the LHRH receptors overexpression by cancer cells.
Export Options
About this article
Cite this article as:
Li Xiaoning, Taratula Oleh, Taratula Olena, Schumann Canan and Minko Tamara, LHRH-Targeted Drug Delivery Systems for Cancer Therapy, Mini-Reviews in Medicinal Chemistry 2017; 17(3) . https://dx.doi.org/10.2174/1389557516666161013111155
DOI https://dx.doi.org/10.2174/1389557516666161013111155 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Homeostasis and the Importance for a Balance Between AKT/mTOR Activity and Intracellular Signaling
Current Medicinal Chemistry Withdrawal Notice: Role, Significance and Association of microRNA-10a/b in Physiology of Cancer
MicroRNA What Makes Y Family Pols Potential Candidates for Molecular Targeted Therapies and Novel Biotechnological Applications
Current Molecular Medicine Inhibitors of Chronically Active Ras: Potential for Treatment of Human Malignancies
Recent Patents on Anti-Cancer Drug Discovery Focal Adhesion Kinase as a Cancer Therapy Target
Anti-Cancer Agents in Medicinal Chemistry The Influence of Macrophages and the Tumor Microenvironment on Natural Killer Cells
Current Molecular Medicine Innate Immunity, Toll-Like Receptors, and Diabetes
Current Immunology Reviews (Discontinued) Role of Oxygen in Cancer: Looking Beyond Hypoxia
Anti-Cancer Agents in Medicinal Chemistry Autophagy : Moving Benchside Promises to Patient Bedsides
Current Cancer Drug Targets Role of Isoprenoid Compounds on Angiogenic Regulation: Opportunities and Challenges
Current Medicinal Chemistry Tetrazole Derivatives as Promising Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Bacterial Protein Toxins: Current and Potential Clinical Use
Current Medicinal Chemistry From the Table to the Bedside: Can Food-Derived Sulforaphane be used as a Novel Agent to Treat Leukemia?
Current Cancer Drug Targets Tailoring NO Donors Metallopharmaceuticals: Ruthenium Nitrosyl Ammines and Aliphatic Tetraazamacrocycles
Current Medicinal Chemistry Burden of Bronchiectasis in Indigenous Peoples - How Can it be Improved?
Current Pediatric Reviews Nanosystems in Drug Targeting: Opportunities and Challenges
Current Nanoscience The Role of Heat Shock Protein (HSP) in Atherosclerosis: Pathophysiology and Clinical Opportunities
Current Medicinal Chemistry Bioavailability of Non-Provitamin A Carotenoids
Current Nutrition & Food Science Genetic Chemoprotection with Mutant O6-Alkylguanine-DNA-Alkyltransferases
Current Gene Therapy Stress Relaxation Testing of Non-Small Lung Cancer Cells Using Atomic Force Microscopy
Current Nanoscience